

# ONTARIO REGULATION 13/10

made under the

## MIDWIFERY ACT, 1991

Made: October 29, 2009

Approved: January 20, 2010

Filed: January 22, 2010

Published on e-Laws: January 22, 2010

Printed in *The Ontario Gazette*: February 6, 2010

Amending O. Reg. 884/93

(Designated Drugs)

Note: Ontario Regulation 884/93 has previously been amended. For the legislative history of the Regulation, see the Table of Consolidated Regulations – Detailed Legislative History at [www.e-Laws.gov.on.ca](http://www.e-Laws.gov.on.ca).

### **1. Section 1 of Ontario Regulation 884/93 is revoked and the following substituted:**

1. For the purposes of paragraph 3 of section 4 of the Act, the following substances are designated as substances that a member may administer by injection on the member's own responsibility:

Ampicillin — for the purpose of preventing neonatal group B streptococcal disease

Bupivacaine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Carbetocin

Carboprost tromethamine

Cefazolin — for the purpose of preventing neonatal group B streptococcal disease

Chloroprocaine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Clindamycin — for the purpose of preventing neonatal group B streptococcal disease

Dimenhydrinate

Diphenhydramine hydrochloride

Epinephrine hydrochloride

Ergonovine maleate

Erythromycin — for the purpose of preventing neonatal group B streptococcal disease

Hepatitis B immune globulin

Hepatitis B vaccine

Intravenous fluids

Lidocaine hydrochloride with or without epinephrine — for the purpose of local anaesthesia for episiotomy or the repair of tears

Measles-mumps-rubella virus vaccine

Oxytocin

Penicillin G — for the purpose of preventing neonatal group B streptococcal disease

Phytonadione

RhD immune globulin

Varicella Zoster immune globulin

### **2. Section 3 of the Regulation is revoked and the following substituted:**

3. For the purposes of paragraph 7 of section 4 of the Act, the following drugs are designated as drugs that a member may prescribe on the member's own responsibility:

Amoxicillin-clavulanic acid — for the purpose of treating mastitis

Cephalexin — for the purpose of treating mastitis

Ciprofloxacin (oral)  
 Clotrimazole  
 Clindamycin (oral)  
 Cloxacillin (oral)  
 Diclofenac (oral)  
 Domperidone — for the purpose of promoting lactation  
 Doxylamine succinate-pyridoxine hydrochloride  
 Ergonovine maleate (oral)  
 Erythromycin ophthalmic ointment  
 Folic acid (oral; greater than 1mg/dose)  
 Hepatitis B immune globulin  
 Hepatitis B vaccine  
 Hydrocortisone anorectal therapy compound  
 Metronidazole (oral)  
 Miconazole  
 Misoprostol — for the purpose of preventing postpartum hemorrhage  
 Mupirocin-betamethasone valerate-miconazole (topical)  
 Naproxen (oral)  
 Nitrofurantoin — for the purpose of treating urinary tract infections  
 Nystatin  
 Phytonadione  
 RhD immune globulin  
 Sulfamethoxazole-trimethoprim (oral)  
 Trimethoprim — for the purpose of treating urinary tract infections

**3. Section 4 of the Regulation is revoked and the following substituted:**

4. (1) In the course of engaging in the practice of midwifery, a member may use any drug on the order of a member of the College of Physicians and Surgeons of Ontario.

(2) For the purposes of paragraph 3 of section 4 of the Act, a member may administer any substance by injection or inhalation on the order of a member of the College of Physicians and Surgeons of Ontario.

**4. This Regulation comes into force on the day it is filed.**

Made by:

COUNCIL OF THE COLLEGE OF MIDWIVES OF ONTARIO:

ANDREA LENNOX  
*President*

DEBORAH ADAMS  
*Registrar & C.E.O.*

Date made: October 29, 2009.